Alkem Labs unit to buy up to 55% of Occlutech

Occlutech, the second-largest player in Europe's minimally invasive cardiac implants segment, posted a revenue of 49.4 million ‌for 2025. It derives about 85% of its revenue from Europe and the ​U.S.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/GeIQ9Dv
via